Drug Discovery and Development in the Cloud

By Bruce Maches

May 21, 2010

I hope that all of you have found the information in my blog so far to be of use to you out there. I have received a comment or two regarding potential approaches in dealing with public cloud validation and will provide an update on that topic in a future entry.

So far we have covered some basic facts on the life sciences companies and the regulatory environment they must exist in. I also explored some of the validation issues around using infrastructure related cloud technologies. In this entry I will start to guide you through the basic steps of drug discovery and development at a high level and point out areas where cloud computing can be leverage to facilitate the drug R&D process, reduce costs, and speed time to market. There is obviously a very broad topic and there is no way to effectively cover this subject in just one blog entry so this theme will be the core of the next several posts.

The pharmaceutical R&D process is a long and arduous procedure lasting up to 10 years or longer. It is also tremendously expensive with some new medications costing up to a billion to get from concept to market. There are a variety of factors that impact the cost and duration of the development effort. A few examples are: if a drug is a new one or a different indication (use) for an existing one, what therapeutic area it is targeted for (cancer, diabetes, etc), and what pathway or disease mechanism is the drug addressing. Given all of these factors, the drug development process can be very risky with many potential new drugs never making it to market after consuming hundreds of millions of dollars in research and development efforts. Industry figures vary but on average only 1 compound out of 5,000 or more make it from concept/discovery through development to the market place.

In layman’s terms, the drug development process can be broken into the following high-level activities:

  • Understanding the targeted disease mechanism within the body.
  • Finding a compound that will disrupt or modify that mechanism, initial FDA filing (patent clock is now ticking!).
  • Drug formulation, toxicity studies, and animal safety studies.
  • Initial human testing, further development work, dosing studies.
  • Large scale clinical testing for effectiveness and side effects.
  • Applying to the FDA for market approval.
  • Post approval monitoring.

Many of the applications used to support these pieces of the R&D process can be very compute and storage intensive making them great candidates for moving into the cloud. Given the nature of the drug development process, requirements for compute and storage resources can vary widely with huge peaks in demand as individual experiments or protocols are executed. This makes a strong case for cloud computing as the cost and time necessary to acquire and deploy these types of systems is simply prohibitive for many life science firms. Small companies clearly do not have the budget or resources available to provision these resources internally, and larger firms are dealing with on-going budget constraints with their R&D expenditures. Cloud computing is well suited for ‘bursty’ types of applications as the resources required can be provisioned on demand and at a much lower cost, reducing capital and operational expenses. Also, using cloud significantly cuts the time required to provision and qualify these resources, allowing life science companies to bring their products to market more quickly.

For this post I will concentrate on the up front set of activities around discovery and screening of new compounds and provide some examples of the different aspects of life sciences research that would benefit from the use of cloud computing.

A very commonly used technique in the biotech field is genomic sequencing, which is an extremely data and computationally intensive process. The technology involves looking for specific amino acid sequences in proteins or DNA samples. The amount of data generated is immense with many experimental runs producing gigabytes of data. All of this data has to be managed, stored and made available for follow on research and analysis. One of the applications used in this field is a piece of software called Basic Local Alignment Search Tool, or BLAST. This tool compares amino acid patterns in the sample being analyzed to a library of nucleotides looking for matches to certain sequences. This type of application is well suited to run in the cloud utilizing CPU and storage resources and then bring the results back to the researcher for further study. Tools such as Amazon’s Elastic Cloud Computing and Simple Storage Service (S3) are prime examples of offerings in this area. In addition, Amazon, along with other vendors, maintains copies of many of the publicly-available data sets on genomic and sequence data and makes them available to their clients as part of their overall cloud environment.

Another promising advance in the drug research process is what is called ‘in silico’ or virtual screening. The promise of virtual screening is that it will allow researchers to greatly increase the pace of finding new potential compounds while reducing costs for lab work and clinical trials. The screening process involves using an automated tool to test thousands of compounds for specific activity, either the inhibition or stimulation of a biochemical or biological mechanism. Running these tests requires the preparation of large numbers of assay plates each with hundreds or thousands of tiny wells. Compounds to be tested are placed in the wells using a pipette mechanism, processed by robotic labs and the corresponding reaction recorded. Using this high throughput technique allows researchers to screen thousands to millions of compounds but it can be costly and time consuming. Virtual screening provides the ability to model the desired reaction using tools such as the protein docking algorithm EADock greatly reducing the number of compound combinations needed to be tested. Leveraging cloud resources to perform ‘in silico’ testing will also cut costs and speed time to market.

Other potential applications for cloud computing include research areas such as protein docking simulations, data mining, and molecular modeling. I will reserve those areas for a future entry.

IT organizations supporting life science R&D functions should work towards creating a service based model for how they provide the resources required for these computational and storage thirsty applications. By understanding the underlying cost models and providing clear standards on how/when/where cloud infrastructure will be deployed, the IT group can better be able to properly manage and secure cloud based resources.

Continued advances in the field of drug discovery will exponentially increase the amount of data generated during the discovery process. IT organizations or vendors that can supply the needed cloud based infrastructure services in a secure and reliable manner will certainly do well in this space. Cloud computing also provides significant flexibility to the researcher as they are now free to explore avenues of research that would not have been feasible before the advent of cloud computing.

Cloud computing is certainly expanding its footprint in the life sciences community. The speed, efficiency and cost effectiveness have made cloud computing an indispensible tool for researchers, allowing them to focus on the ‘what’ of science and not the ‘how.’ Having the resources to do better research at this phase of the drug development process will also reduce time and expense in the later phases. My next post will expand further on the challenges and opportunities in the discovery phase of the pharmaceutical research process.

I would love to hear from you if you have any questions or comments. Feel free to contact me at brmaches@brmachesassociates.com.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

UCSD, AIST Forge Tighter Alliance with AI-Focused MOU

January 18, 2018

The rich history of collaboration between UC San Diego and AIST in Japan is getting richer. The organizations entered into a five-year memorandum of understanding on January 10. The MOU represents the continuation of a 1 Read more…

By Tiffany Trader

New Blueprint for Converging HPC, Big Data

January 18, 2018

After five annual workshops on Big Data and Extreme-Scale Computing (BDEC), a group of international HPC heavyweights including Jack Dongarra (University of Tennessee), Satoshi Matsuoka (Tokyo Institute of Technology), Read more…

By John Russell

Researchers Measure Impact of ‘Meltdown’ and ‘Spectre’ Patches on HPC Workloads

January 17, 2018

Computer scientists from the Center for Computational Research, State University of New York (SUNY), University at Buffalo have examined the effect of Meltdown and Spectre security updates on the performance of popular H Read more…

By Tiffany Trader

HPE Extreme Performance Solutions

HPE and NREL Take Steps to Create a Sustainable, Energy-Efficient Data Center with an H2 Fuel Cell

As enterprises attempt to manage rising volumes of data, unplanned data center outages are becoming more common and more expensive. As the cost of downtime rises, enterprises lose out on productivity and valuable competitive advantage without access to their critical data. Read more…

Fostering Lustre Advancement Through Development and Contributions

January 17, 2018

Six months after organizational changes at Intel's High Performance Data (HPDD) division, most in the Lustre community have shed any initial apprehension around the potential changes that could affect or disrupt Lustre Read more…

By Carlos Aoki Thomaz

UCSD, AIST Forge Tighter Alliance with AI-Focused MOU

January 18, 2018

The rich history of collaboration between UC San Diego and AIST in Japan is getting richer. The organizations entered into a five-year memorandum of understandi Read more…

By Tiffany Trader

New Blueprint for Converging HPC, Big Data

January 18, 2018

After five annual workshops on Big Data and Extreme-Scale Computing (BDEC), a group of international HPC heavyweights including Jack Dongarra (University of Te Read more…

By John Russell

Researchers Measure Impact of ‘Meltdown’ and ‘Spectre’ Patches on HPC Workloads

January 17, 2018

Computer scientists from the Center for Computational Research, State University of New York (SUNY), University at Buffalo have examined the effect of Meltdown Read more…

By Tiffany Trader

Fostering Lustre Advancement Through Development and Contributions

January 17, 2018

Six months after organizational changes at Intel's High Performance Data (HPDD) division, most in the Lustre community have shed any initial apprehension aroun Read more…

By Carlos Aoki Thomaz

When the Chips Are Down

January 11, 2018

In the last article, "The High Stakes Semiconductor Game that Drives HPC Diversity," I alluded to the challenges facing the semiconductor industry and how that may impact the evolution of HPC systems over the next few years. I thought I’d lift the covers a little and look at some of the commercial challenges that impact the component technology we use in HPC. Read more…

By Dairsie Latimer

How Meltdown and Spectre Patches Will Affect HPC Workloads

January 10, 2018

There have been claims that the fixes for the Meltdown and Spectre security vulnerabilities, named the KPTI (aka KAISER) patches, are going to affect applicatio Read more…

By Rosemary Francis

Momentum Builds for US Exascale

January 9, 2018

2018 looks to be a great year for the U.S. exascale program. The last several months of 2017 revealed a number of important developments that help put the U.S. Read more…

By Alex R. Larzelere

ANL’s Rick Stevens on CANDLE, ARM, Quantum, and More

January 8, 2018

Late last year HPCwire caught up with Rick Stevens, associate laboratory director for computing, environment and life Sciences at Argonne National Laboratory, f Read more…

By John Russell

Inventor Claims to Have Solved Floating Point Error Problem

January 17, 2018

"The decades-old floating point error problem has been solved," proclaims a press release from inventor Alan Jorgensen. The computer scientist has filed for and Read more…

By Tiffany Trader

US Coalesces Plans for First Exascale Supercomputer: Aurora in 2021

September 27, 2017

At the Advanced Scientific Computing Advisory Committee (ASCAC) meeting, in Arlington, Va., yesterday (Sept. 26), it was revealed that the "Aurora" supercompute Read more…

By Tiffany Trader

Japan Unveils Quantum Neural Network

November 22, 2017

The U.S. and China are leading the race toward productive quantum computing, but it's early enough that ultimate leadership is still something of an open questi Read more…

By Tiffany Trader

AMD Showcases Growing Portfolio of EPYC and Radeon-based Systems at SC17

November 13, 2017

AMD’s charge back into HPC and the datacenter is on full display at SC17. Having launched the EPYC processor line in June along with its MI25 GPU the focus he Read more…

By John Russell

Nvidia Responds to Google TPU Benchmarking

April 10, 2017

Nvidia highlights strengths of its newest GPU silicon in response to Google's report on the performance and energy advantages of its custom tensor processor. Read more…

By Tiffany Trader

IBM Begins Power9 Rollout with Backing from DOE, Google

December 6, 2017

After over a year of buildup, IBM is unveiling its first Power9 system based on the same architecture as the Department of Energy CORAL supercomputers, Summit a Read more…

By Tiffany Trader

Fast Forward: Five HPC Predictions for 2018

December 21, 2017

What’s on your list of high (and low) lights for 2017? Volta 100’s arrival on the heels of the P100? Appearance, albeit late in the year, of IBM’s Power9? Read more…

By John Russell

Chip Flaws ‘Meltdown’ and ‘Spectre’ Loom Large

January 4, 2018

The HPC and wider tech community have been abuzz this week over the discovery of critical design flaws that impact virtually all contemporary microprocessors. T Read more…

By Tiffany Trader

Leading Solution Providers

Perspective: What Really Happened at SC17?

November 22, 2017

SC is over. Now comes the myriad of follow-ups. Inboxes are filled with templated emails from vendors and other exhibitors hoping to win a place in the post-SC thinking of booth visitors. Attendees of tutorials, workshops and other technical sessions will be inundated with requests for feedback. Read more…

By Andrew Jones

Tensors Come of Age: Why the AI Revolution Will Help HPC

November 13, 2017

Thirty years ago, parallel computing was coming of age. A bitter battle began between stalwart vector computing supporters and advocates of various approaches to parallel computing. IBM skeptic Alan Karp, reacting to announcements of nCUBE’s 1024-microprocessor system and Thinking Machines’ 65,536-element array, made a public $100 wager that no one could get a parallel speedup of over 200 on real HPC workloads. Read more…

By John Gustafson & Lenore Mullin

Delays, Smoke, Records & Markets – A Candid Conversation with Cray CEO Peter Ungaro

October 5, 2017

Earlier this month, Tom Tabor, publisher of HPCwire and I had a very personal conversation with Cray CEO Peter Ungaro. Cray has been on something of a Cinderell Read more…

By Tiffany Trader & Tom Tabor

Flipping the Flops and Reading the Top500 Tea Leaves

November 13, 2017

The 50th edition of the Top500 list, the biannual publication of the world’s fastest supercomputers based on public Linpack benchmarking results, was released Read more…

By Tiffany Trader

How Meltdown and Spectre Patches Will Affect HPC Workloads

January 10, 2018

There have been claims that the fixes for the Meltdown and Spectre security vulnerabilities, named the KPTI (aka KAISER) patches, are going to affect applicatio Read more…

By Rosemary Francis

GlobalFoundries, Ayar Labs Team Up to Commercialize Optical I/O

December 4, 2017

GlobalFoundries (GF) and Ayar Labs, a startup focused on using light, instead of electricity, to transfer data between chips, today announced they've entered in Read more…

By Tiffany Trader

HPC Chips – A Veritable Smorgasbord?

October 10, 2017

For the first time since AMD's ill-fated launch of Bulldozer the answer to the question, 'Which CPU will be in my next HPC system?' doesn't have to be 'Whichever variety of Intel Xeon E5 they are selling when we procure'. Read more…

By Dairsie Latimer

Nvidia, Partners Announce Several V100 Servers

September 27, 2017

Here come the Volta 100-based servers. Nvidia today announced an impressive line-up of servers from major partners – Dell EMC, Hewlett Packard Enterprise, IBM Read more…

By John Russell

  • arrow
  • Click Here for More Headlines
  • arrow
Share This